Skip to main content
. 2023 May 24;26(6):106954. doi: 10.1016/j.isci.2023.106954

Figure 4.

Figure 4

Therapeutic effects of donepezil with respect to COVID-19

(A) Adv inoculation, donepezil administration, behavior experiment schedules.

(B) Decreased S1 mouse swimming time in WFST, i.e., increase in fatigue, and therapeutic effect of donepezil (no treatment; vector control, n = 10, S1 mouse, n = 10; Mann-Whitney U-test; median values; ∗∗∗, p < 0.001. Donepezil; vector control, n = 10 S1 mouse, n = 10; Mann-Whitney U-test; median values; ns, not significant).

(C) Increased immobility time in S1 mouse TST and therapeutic effect of donepezil (no treatment; vector control, n = 7, S1 mouse, n = 8; Mann-Whitney U-test; median values; ∗, p < 0.05. Donepezil; vector control, n = 10 S1 mouse, n = 10; Mann-Whitney U-test; median values; ns, not significant).

(D) Adv inoculation, donepezil administration, organ harvest schedules.

(E) Inhibitory effect of donepezil on TNFα expression in S1 mouse brain tissue (0 mg/kg, n = 5; 1 mg/kg, n = 5; Mann-Whitney U-test; median values).

(F) Inhibitory effect of donepezil on IL-6 expression in S1 mouse brain tissue (0 mg/kg, n = 5; 1 mg/kg, n = 5; Mann-Whitney U-test; median values).

(G) Inhibitory effect of donepezil on CCL2 expression in S1 mouse brain tissue (0 mg/kg, n = 5; 1 mg/kg, n = 5; Mann-Whitney U-test; median values).